NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Appraisal

Etanercept, abatacept, adalimumab and tocilizumab for treating juvenile idiopathic arthritis (including review of TA35)

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors AbbVie Bristol Myers Squibb Pfizer Roche Products Patient/carer groups Action for Children Action on Pain Afiya Trust Arthritic Association Arthritis Care Arthritis Care Back Care Black Health Agency Children's Chronic Arthritis Association Disability Rights UK Equalities National Council Leonard Cheshire Disability Muslim Health Network National Children's Bureau National Parent Partnership Network National Rheumatoid Arthritis Society Pain Concern Pain UK South Asian Health Foundation Specialised Healthcare Alliance Wellchild	General • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium Comparator manufacturers • None Relevant research groups • Arthritis Research UK • Health Research Authority • MRC Clinical Trials Unit • National Institute for Health Research • Society for Back Pain Research Health Technology Assessment Programme • Southampton Health Technology Assessment Centre Associated Guideline Groups

National Institute for Health and Care Excellence

Provisional matrix for the technology appraisal of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (including review of TA35) Issue date: July 2014